Literature DB >> 6611112

Positron imaging in ischemic stroke disease.

R H Ackerman, N M Alpert, J A Correia, S Finklestein, S M Davis, R E Kelley, G A Donnan, J G D'Alton, J M Taveras.   

Abstract

Positron emission tomography (PET) is well suited to the study of ischemic stroke disease. It has the potential to help elucidate pathophysiological mechanisms, differentiate viable from nonviable tissue, and provide a more rational basis for developing specific therapies for ischemic lesions. The different tracer strategies that may be applied to the study of ischemic disease, however, all have relative limitations, which may be related to the physical or biological determinants of the tracer distributions, to the tracer half-lives, or to the methods required for quantitation of the data. Determination of blood flow and oxygen metabolism are useful for characterizing stroke lesions, but other parameters, such as the oxygen extraction fraction, blood volume, and glucose metabolism, can provide important interpretative information. Correlation of the physiological PET data with the clinical presentation and course is a primary requisite for the development of the full potential of PET.

Entities:  

Mesh:

Year:  1984        PMID: 6611112     DOI: 10.1002/ana.410150724

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  3 in total

1.  Topographic EEG mapping in cerebrovascular disease.

Authors:  K Nagata
Journal:  Brain Topogr       Date:  1989 Fall-Winter       Impact factor: 3.020

Review 2.  Topographic EEG in brain ischemia--correlation with blood flow and metabolism.

Authors:  K Nagata
Journal:  Brain Topogr       Date:  1988       Impact factor: 3.020

3.  Reliability of cerebral blood volume maps as a substitute for diffusion-weighted imaging in acute ischemic stroke.

Authors:  Amy R Deipolyi; Ona Wu; Eric A Macklin; Pamela W Schaefer; Lee H Schwamm; R Gilberto Gonzalez; William A Copen
Journal:  J Magn Reson Imaging       Date:  2012-07-03       Impact factor: 4.813

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.